Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

Hepatology

Volumn 65, Issue 6, 2017, Pages 1810-1822

  Fernández Carrillo, Carlos ^a   Lens, Sabela ^b   Llop, Elba ^a   Pascasio, Juan Manuel ^c   Crespo, Javier ^d   Arenas, Juan ^e   Fernández, Inmaculada ^f   Baliellas, Carme ^g   Carrión, José Antonio ^h   de la Mata, Manuel ⁱ   Buti, Maria ^j   Castells, Lluís ^j   Albillos, Agustín ^k   Romero, Manuel ^l   Turnes, Juan ^m   Pons, Clara ⁿ   Moreno Planas, José María ^o   Moreno Palomares, José Javier ^p   Fernández Rodriguez, Conrado ^q   García Samaniego, Javier ^r   Prieto, Martín ^s   Fernández Bermejo, Miguel ^t   Salmerón, Javier ^u   Badia, Ester ^v   Salcedo, Magdalena ^w   Herrero, José Ignacio ^x   Granados, Rafael ^y   Blé, Michel ^z   Mariño, Zoe ^b   Calleja, José Luis ^a   more..

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL DONOSTIA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^m Instituto de Investigación Sanitaria Galicia Sur   (Spain)

ⁿ HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^p HOSPITAL GENERAL DE SEGOVIA   (Spain)

^q HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^r HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^s HOSPITAL UNIVERSITARIO LA FE   (Spain)

^t HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^u HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^v HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^w HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^x UNIVERSITY CLINIC OF NAVARRA   (Spain)

^y HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^z Servidigest Clinic of Barcelona   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; DACLATASVIR; LEDIPASVIR; PROTHROMBIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CHILD PUGH SCORE; CLINICAL PRACTICE; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; END STAGE LIVER DISEASE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FUNCTION; LIVER STIFFNESS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SPAIN; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; TRANSIENT ELASTOGRAPHY; TREATMENT DURATION; CAUSE OF DEATH; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CAUSE OF DEATH; COHORT STUDIES; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SOFOSBUVIR; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85018986119     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29097     Document Type: Article

References (49)

1. World Health Organization. Hepatitis C fact sheet No. 164. http://www.who.int/mediacentre/factsheets/fs164/en. Updated July 2015. Accessed May 2016.
2. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52.
3. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441.
4. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim H-Y, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405.
5. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virologic response in veterans with hepatitis C virus infection. Hepatology 2016;64:130-137.
6. Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis—pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepatol 2016;23:408-418.
7. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
8. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-1493.
9. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-1888.
10. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.
11. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
12. Poordad F, Hézode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
13. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147:359-365.
14. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
15. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
16. Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology 2015;148:762-770.
17. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-659.
18. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-697.
19. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology 2016;63:1493-1505.
20. Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64:1224-1231.
21. Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 2016;64:360-369.
22. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-337.
23. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour J-F, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-2593.
24. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516.
25. Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 2013;56:1646-1653.
26. Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol 2015;13:1846-1853.
27. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 2015;373:2618-2628.
28. Welker MW, Luhne S, Lange CM, Vermehren J, Farnik H, Herrmann E, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol 2016;64:790-799.
29. Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016;64:234-238.
30. Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015;60:1031-1035.
31. Zlotnik A, Abraira V. A general-purpose nomogram generator for predictive logistic regression models. Stata J 2015;12:537-546.
32. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-726.
33. The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma. J Hepatol 2016;65:734-740.
34. Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int 2017;11:38-44.
35. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
36. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015;62:79-86.
37. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
38. Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015;35:1923-1933.
39. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-156.
40. Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 2015;62:1004-1012.
41. Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-747.
42. Afdhal N, Asselah T, Everson GT, Bosch J, De-Oertel S, Brainard DM, et al. HCV eradication results in reduction of hepatic venous pressure gradient 48 weeks after end of treatment; final results of the study of sofosbuvir plus ribavirin in patents with cirrhosis and portal hypertension. Presented at: The International Liver Congress, European Association for the Study of the Liver (EASL); April, 13–17, 2016; Barcelona, Spain.
43. Lens S, Alvarado-Tapias E, Mariño Z, Londoño M-C, Llop E, González JM, et al. Impact of all-oral antiviral therapy on portal pressure and hemodynamics on HCV-infected cirrhotic patients. Hepatology 64(Suppl. 1):Abstract 58.
44. European Medicines Agency. Summary of product characteristics [Olysio]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002777/WC500167867.pdf. Accessed May 2016.
45. Soriano V, Barreiro P, de Mendoza C, Peña JM. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther 2016;21:91-92.
46. US Food and Drug Administration. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), copackaged for oral use. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm458365.htm. Accessed August 2016.
47. Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology 2015;62:715-725.
48. Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 2016;65:524-531.
49. Pascasio JM, Vinaixa C, Ferrer MT, Colmenero J, Rubin A, Castells L, et al. Interferon (IFN)-free antiviral therapy in cirrhotic patients infected with hepatitis C on the waiting list for liver transplantation. Efficacy and impact on delisting and liver function. J Hepatol 2016;64:S543.